Late diagnosis of late onset Fabry disease

Timothy G Scully1, Heather Chalinor1, James Theuerle2

  • 1Cardiology, Austin Health, Heidelberg, Victoria, Australia.

BMJ Case Reports
|June 29, 2026
PubMed

Insights

Early genetic screening and advanced imaging are crucial for diagnosing left ventricular hypertrophy (LVH). This case reveals how adult-onset Fabry disease, linked to the GLA gene, can mimic other heart conditions, emphasizing timely diagnosis.

Area of Science:

  • Cardiology
  • Genetics
  • Medical Diagnostics

Background:

  • Left ventricular hypertrophy (LVH) is a common cardiac finding.
  • Initial diagnosis of hypertrophic cardiomyopathy can sometimes overlook underlying genetic causes.
  • Delayed diagnosis of conditions like Fabry disease can lead to advanced heart failure.

Purpose of the Study:

  • To highlight the diagnostic challenges in patients presenting with LVH.
  • To emphasize the importance of genetic testing in unexplained cardiac conditions.
  • To showcase the role of advanced imaging in cardiac diagnosis.

Main Methods:

  • Transthoracic echocardiogram for initial LVH detection.
  • Cardiac MRI to assess myocardial scarring.
  • Endomyocardial biopsy for histological examination.
  • Genetic testing for GLA gene variants.

Main Results:

  • A patient initially diagnosed with hypertrophic cardiomyopathy later developed decompensated heart failure.
  • Cardiac MRI revealed extensive scarring, leading to a presumptive diagnosis of cardiac amyloidosis.
  • Endomyocardial biopsy was non-diagnostic for the cause of LVH.
  • Genetic testing identified a GLA gene variant, indicating adult-onset Fabry disease.

Conclusions:

  • Genetic testing is essential for diagnosing inherited cardiomyopathies.
  • Advanced imaging modalities like cardiac MRI aid in characterizing cardiac pathology.
  • Early identification of Fabry disease through genetic screening can prevent disease progression and improve patient outcomes.

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...